InteRNA Technologies last week announced that it is collaborating with the University of Bonn and Belgian biopharmaceutical firm UCB to identify and study microRNAs as therapeutic targets for neurodegenerative diseases.
According to the company, the alliance is part of the Neuroallianz Consortium, a German-funded academic-industry alliance focused on developing treatments for neurodegenerative conditions.
Specific terms of the partnership were not disclosed.